Qingyuan Zhang
Qingdao University(CN)Harbin Medical University(CN)Guangxi Medical University(CN)China University of Mining and Technology(CN)Third Affiliated Hospital of Harbin Medical University(CN)Affiliated Hospital of Qingdao University(CN)Shenyang Research Institute of Foundry(CN)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial(2015)301 cited
- → Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)264 cited
- → Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer(2019)227 cited
- → Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance(2020)203 cited
- → Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer(2024)191 cited
- → FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect